Cargando…

Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice

INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of femal...

Descripción completa

Detalles Bibliográficos
Autores principales: Stabellini, Nickolas, Bruno, Debora S., Dmukauskas, Mantas, Barda, Amie J., Cao, Lifen, Shanahan, John, Waite, Kristin, Montero, Alberto J., Barnholtz-Sloan, Jill S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983352/
https://www.ncbi.nlm.nih.gov/pubmed/35400080
http://dx.doi.org/10.1016/j.jtocrr.2022.100307
_version_ 1784681968369139712
author Stabellini, Nickolas
Bruno, Debora S.
Dmukauskas, Mantas
Barda, Amie J.
Cao, Lifen
Shanahan, John
Waite, Kristin
Montero, Alberto J.
Barnholtz-Sloan, Jill S.
author_facet Stabellini, Nickolas
Bruno, Debora S.
Dmukauskas, Mantas
Barda, Amie J.
Cao, Lifen
Shanahan, John
Waite, Kristin
Montero, Alberto J.
Barnholtz-Sloan, Jill S.
author_sort Stabellini, Nickolas
collection PubMed
description INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of females to treatment. The primary objective of this work is to analyze and describe outcome differences between males and females diagnosed with having lung cancer. METHODS: Data were obtained from a large hybrid academic-community practice institution and validated with Surveillance, Epidemiology, and End Results (SEER). The initial cohort included patients aged more than or equal to 18 years diagnosed with having primary malignant lung cancer. Patients were excluded from the analysis if they had an unknown diagnosis date, were missing sex, or had prior history of cancer. Chi-square, t test, and Kruskal-Wallis tests were used to compare characteristics of males and females. Risks were estimated by logistic and Cox regressions. RESULTS: A total of 8909 patients from our institution and 725,018 in SEER were analyzed. Male-to-female ratio was 1.0. Females were more likely to undergo surgery and less likely to be treated with immunotherapy. Females had higher rates of documented psychological affections, depression, anxiety, urinary tract infection, hypothyroidism, and hyperthyroidism, while displaying lower rates of acute kidney injury, myocardial infarction, and myocarditis. Paired multivariable models revealed a lower risk of death for females in SEER (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08) and equal risks in our institution (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08). CONCLUSIONS: Female sex was associated with higher surgical rates, lower immunotherapy use rates, higher rates of endocrinologic complications after immunotherapy use, and higher rates of psychological disorders.
format Online
Article
Text
id pubmed-8983352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89833522022-04-07 Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice Stabellini, Nickolas Bruno, Debora S. Dmukauskas, Mantas Barda, Amie J. Cao, Lifen Shanahan, John Waite, Kristin Montero, Alberto J. Barnholtz-Sloan, Jill S. JTO Clin Res Rep Original Article INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of females to treatment. The primary objective of this work is to analyze and describe outcome differences between males and females diagnosed with having lung cancer. METHODS: Data were obtained from a large hybrid academic-community practice institution and validated with Surveillance, Epidemiology, and End Results (SEER). The initial cohort included patients aged more than or equal to 18 years diagnosed with having primary malignant lung cancer. Patients were excluded from the analysis if they had an unknown diagnosis date, were missing sex, or had prior history of cancer. Chi-square, t test, and Kruskal-Wallis tests were used to compare characteristics of males and females. Risks were estimated by logistic and Cox regressions. RESULTS: A total of 8909 patients from our institution and 725,018 in SEER were analyzed. Male-to-female ratio was 1.0. Females were more likely to undergo surgery and less likely to be treated with immunotherapy. Females had higher rates of documented psychological affections, depression, anxiety, urinary tract infection, hypothyroidism, and hyperthyroidism, while displaying lower rates of acute kidney injury, myocardial infarction, and myocarditis. Paired multivariable models revealed a lower risk of death for females in SEER (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08) and equal risks in our institution (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08). CONCLUSIONS: Female sex was associated with higher surgical rates, lower immunotherapy use rates, higher rates of endocrinologic complications after immunotherapy use, and higher rates of psychological disorders. Elsevier 2022-03-09 /pmc/articles/PMC8983352/ /pubmed/35400080 http://dx.doi.org/10.1016/j.jtocrr.2022.100307 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Stabellini, Nickolas
Bruno, Debora S.
Dmukauskas, Mantas
Barda, Amie J.
Cao, Lifen
Shanahan, John
Waite, Kristin
Montero, Alberto J.
Barnholtz-Sloan, Jill S.
Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title_full Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title_fullStr Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title_full_unstemmed Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title_short Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
title_sort sex differences in lung cancer treatment and outcomes at a large hybrid academic-community practice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983352/
https://www.ncbi.nlm.nih.gov/pubmed/35400080
http://dx.doi.org/10.1016/j.jtocrr.2022.100307
work_keys_str_mv AT stabellininickolas sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT brunodeboras sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT dmukauskasmantas sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT bardaamiej sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT caolifen sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT shanahanjohn sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT waitekristin sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT monteroalbertoj sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice
AT barnholtzsloanjills sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice